Gossamer Bio (NASDAQ:GOSS) Hits New 1-Year High – Time to Buy?

by · The Cerbat Gem

Gossamer Bio, Inc. (NASDAQ:GOSS – Get Free Report)’s share price reached a new 52-week high during trading on Thursday . The company traded as high as $3.73 and last traded at $3.7550, with a volume of 697671 shares traded. The stock had previously closed at $3.49.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Gossamer Bio in a research note on Thursday, September 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Gossamer Bio in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Gossamer Bio from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Check Out Our Latest Report on GOSS

Gossamer Bio Stock Performance

The business has a fifty day simple moving average of $2.71 and a 200-day simple moving average of $2.20. The stock has a market capitalization of $830.48 million, a P/E ratio of -5.20 and a beta of 1.92.

Gossamer Bio (NASDAQ:GOSS – Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The business had revenue of $13.29 million for the quarter, compared to the consensus estimate of $6.32 million. Gossamer Bio had a negative net margin of 354.50% and a negative return on equity of 1,774.72%. On average, sell-side analysts anticipate that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year.

Institutional Investors Weigh In On Gossamer Bio

Several large investors have recently added to or reduced their stakes in GOSS. Legal & General Group Plc purchased a new position in shares of Gossamer Bio during the second quarter valued at approximately $26,000. Ciovacco Capital Management LLC purchased a new stake in shares of Gossamer Bio in the 3rd quarter worth about $27,000. Banco BTG Pactual S.A. bought a new stake in shares of Gossamer Bio during the 2nd quarter valued at about $27,000. Drive Wealth Management LLC increased its position in shares of Gossamer Bio by 52.7% during the second quarter. Drive Wealth Management LLC now owns 25,474 shares of the company’s stock valued at $31,000 after buying an additional 8,797 shares during the period. Finally, Brighton Jones LLC bought a new position in Gossamer Bio in the third quarter worth about $36,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

(Get Free Report)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

Recommended Stories